SCHEMBL836745

SCHEMBL836745

O=C(O)c1nc2ccccc2s1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.65
RAB9A P51151 4/20 0.65
HPGD P15428 4/20 0.65
NPC1 O15118 3/20 0.65
PKM P14618 1/20 0.65
NFKB1 P19838 1/20 0.65
NFKB2 Q00653 1/20 0.65
RELA Q04206 1/20 0.65
ALDH1A1 P00352 4/20 0.64
MEN1 O00255 2/20 0.60
MAPT P10636 2/20 0.60
KMT2A Q03164 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
L3MBTL1 Q9Y468 3/20 0.59
LMNA P02545 2/20 0.58
TSHR P16473 2/20 0.58
ALOX15 P16050 2/20 0.58
CASP1 P29466 1/20 0.58
MAPK1 P28482 2/20 0.56
HSD17B1 P14061 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28727291 1.00 SMN1; SMN2 (0.65) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL27714204 0.98 SMN1; SMN2 (0.63) SMN1; SMN2RAB9AHPGDNPC1PKM
Hydrochloric Acid SCHEMBL3610419 0.98 SMN1; SMN2 (0.63) SMN1; SMN2RAB9AHPGDNPC1PKM
Benzo[D]Thiazole SCHEMBL28216365 0.87 ALDH1A1 (0.58) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL6319718 0.86 ALDH1A1 (0.66) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL2732845 0.85 SMN1; SMN2 (0.61) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL2170056 0.84 ALDH1A1 (0.64) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL24751 0.83 HSD17B1 (0.62) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL14020195 0.83 NPC1 (0.55) SMN1; SMN2RAB9AHPGDNPC1PKM
SCHEMBL369480 0.82 ALDH1A1 (0.62) SMN1; SMN2RAB9AHPGDNPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977957-A Small-molecule proteasome agonist and preparation method and application thereof 杭州市第一人民医院(西湖大学附属杭州市第一人民医院) 2025-05-13 CN claimed
CN-108350034-B Antimicrobial polymyxin derived compounds 莫纳什大学 2022-03-11 CN claimed
US-20170341956-A1 SYSTEM FOR DYNAMIC FLUIDIZED LOADING OF A LIGAND UPON CARBON MEDIA AND METHODS ASSOCIATED THEREWITH Tusaar Corp. 2017-11-30 US claimed
CN-105198835-B The synthesis technique of the formic acid of benzothiazole 2 上海泰坦科技股份有限公司 2017-09-29 CN claimed
CN-104860901-B Preparation method of benzothiazole-2-carboxylic acid 北京工业大学 2017-04-19 CN claimed
CN-105198835-A Synthesizing process of benzothiazole-2-formic acid SHANGHAI TITAN TECHNOLOGY CO LTD 2015-12-30 CN claimed
CN-104860901-A Preparation method of benzothiazole-2-carboxylic acid UNIV BEIJING TECHNOLOGY 2015-08-26 CN claimed
EP-2794490-A1 SYSTEM FOR DYNAMIC FLUIDIZED LOADING OF A LIGAND UPON CARBON MEDIA AND METHODS ASSOCIATED THEREWITH Tusaar Inc (US) 2014-10-29 EP claimed
CN-103923765-A Detergent Composition For Process Of Manufacturing Semiconductors And Displays COWON INNOTECH INC 2014-07-16 CN claimed
US-8598175-B2 Heteroarylamide pyrimidone derivatives SANOFI (FR) 2013-12-03 US claimed
EP-2162443-A2 HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Sanofi-Aventis (FR) 2010-03-17 EP claimed
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 US claimed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 US claimed
WO-2008155666-A2 HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI-AVENTIS (FR) 2008-12-24 WO claimed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 WO claimed
EP-1992621-A1 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases Sanofi-Aventis (FR) 2008-11-19 EP claimed
WO-2007138112-A2 COMPOUNDS THAT INTERACT WITH ION CHANNELS, IN PARTICULAR WITH ION CHANNELS FROM THE KV FAMILY DEVGEN N.V. (BE) 2007-12-06 WO claimed
CN-1248968-A Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCRI receptor PFIZER (US) 2000-03-29 CN claimed
EP-0966443-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1999-12-29 EP claimed
WO-1998038167-A1 HETEROARYL-HEXANOIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS SELECTIVE INHIBITORS OF MIP-1-ALPHA BINDING TO ITS CCR1 RECEPTOR PFIZER INC. (US) 1998-09-03 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME QDPR, ADM2, PDE3B SMN1; SMN2 2444/4885RAB9A 314/4885HPGD 591/4885
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 SMN1; SMN2 4144/4885RAB9A 3569/4885HPGD 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.